You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Cadonilimab (AK104)

Showing 1 - 25 of 642
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Endometrial Cancer, Endometrial Adenocarcinoma Trial (Cadonilimab, Carboplatin, Cisplatin)

Not yet recruiting
  • Endometrial Cancer
  • Endometrial Adenocarcinoma
  • (no location specified)
Oct 7, 2023

Endometrial Cancer, Endometrial Adenocarcinoma Trial in Guangzhou (Cadonilimab, Lenvatinib)

Not yet recruiting
  • Endometrial Cancer
  • Endometrial Adenocarcinoma
  • Guangzhou, China
    Sun Yat-sen University Cancer Cetntre
Apr 9, 2023

Nasopharyngeal Carcinoma Trial in Wuhan (Cadonilimab)

Recruiting
  • Nasopharyngeal Carcinoma
  • Wuhan, Hubei, China
    Union Hospital, Tongji Medical College, Huazhong University of S
Mar 27, 2023

NSCLC Trial in Wuhan (Cadonilimab, Pemetrexed, Carboplatin)

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Wuhan, Hubei, China
    Qian Chu
Aug 18, 2023

Bladder Cancer Trial in Tianjin (Cadonilimab)

Recruiting
  • Bladder Cancer
  • Tianjin, Tianjin, China
    Tianjin Medical University Second Hospital
Aug 23, 2023

Clear Cell Renal Cell Carcinoma?Resistance to Immunotherapy Trial in Shanghai (AK104(anti-PD-1/CTLA-4 bi-specific antibody

Recruiting
  • Clear Cell Renal Cell Carcinoma、Resistance to Immunotherapy
  • AK104（anti-PD-1/CTLA-4 bi-specific antibody ，intravenously）,lenvatinib（ targeted VEGFR 1-3、FGFR、PDGFRα， small molecule TKI，orally
  • Shanghai, Shanghai, China
    Shanghai Renji Hospital
Sep 12, 2023

Colorectal Cancer Trial in Guangzhou (mFOLFOXIRI + Cadonilimab, mFOLFOX6)

Not yet recruiting
  • Colorectal Cancer
  • Guangzhou, Guangdong, China
    Gastrointestinal Hospital, Sun Yat-sen University
Oct 17, 2022

Gastric Cancer Trial (S-1, Oxaliplatin, Cadonilimab)

Not yet recruiting
  • Gastric Cancer
  • S-1, Oxaliplatin, Cadonilimab
  • (no location specified)
Jul 10, 2023

Immunotherapy, Second-line Treatment Trial in Guizhou (Cadonilimab)

Recruiting
  • Immunotherapy
  • Second-line Treatment
  • Guizhou, ZunYi, China
    The Second Affiliated Hospital of Zunyi Medical University
Jun 14, 2023

AK104 Combined With I-125 Brachytherapy for Recurrent or

Not yet recruiting
  • Cervical Cancer
  • Iodine-125 particle brachytherapy
  • AK104
  • (no location specified)
Sep 25, 2023

Resectable Esophageal Squamous Cell Carcinoma, Neoadjuvant Therapy Trial (cadonilimab+chemo)

Not yet recruiting
  • Resectable Esophageal Squamous Cell Carcinoma
  • Neoadjuvant Therapy
  • (no location specified)
Apr 18, 2023

Carcinomas, Cervix Cancer, Cervical Cancer Trial in Houston (AK104)

Recruiting
  • Carcinomas
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Oct 12, 2022

Clear Cell Renal Cell Carcinoma, First-line Treatment Trial in Shanghai (AK104, axitinib)

Not yet recruiting
  • Clear Cell Renal Cell Carcinoma
  • First-line Treatment
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Feb 16, 2022

Locally Advanced Rectal Cancer Trial in Guangzhou (AK104, Capecitabine, Neoadjuvant Radiotherapy)

Not yet recruiting
  • Locally Advanced Rectal Cancer
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Aug 5, 2023

Nasopharyngeal Carcinoma, Immune Checkpoint Inhibitors Trial (Cadonilimab, Gemcitabine, Cisplatin)

Not yet recruiting
  • Nasopharyngeal Carcinoma
  • Immune Checkpoint Inhibitors
  • (no location specified)
Jun 1, 2023

Muscle Invasive Bladder Carcinoma Trial in Beijing (RC48-ADC, AK104)

Recruiting
  • Muscle Invasive Bladder Carcinoma
  • Beijing, China
    Cancer Institute and Hospital, Chinese Academy of Medical Scienc
Oct 6, 2023

Pleural Mesothelioma Trial in Guangzhou (Cadonilimab+Bevacizumab+Pemetrexed+Carboplatin)

Not yet recruiting
  • Pleural Mesothelioma
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Jul 3, 2023

Cervical Cancer Trial in Wuhan (Cadonilimab, Anlotinib)

Recruiting
  • Cervical Cancer
  • Wuhan, Hubei, China
    Zhongnan Hospital of Wuhan University
Apr 5, 2023

Bile Duct Adenocarcinoma Trial in Hangzhou (surufatinib plus cadonilimab)

Recruiting
  • Bile Duct Adenocarcinoma
  • surufatinib plus cadonilimab
  • Hangzhou, Zhejiang, China
    Zhejiang Cancer Hospital
Oct 15, 2023

Esophagus Cancer Trial in Guangzhou (Cadonilimab, Paclitaxel and cisplatin, intensity-modulated radiotherapy)

Not yet recruiting
  • Esophagus Cancer
  • Guangzhou, Guangdong, China
    Sun Yat-sen University
Nov 20, 2023

Resectable Hepatocellular Carcinoma Trial (Cadonilimab, TACE, Surgery)

Not yet recruiting
  • Resectable Hepatocellular Carcinoma
  • (no location specified)
Dec 12, 2022

Nasopharyngeal Carcinoma, Immune Checkpoint Inhibitor, Radiotherapy Trial (radiation, drug, biological)

Not yet recruiting
  • Nasopharyngeal Carcinoma
  • +3 more
  • Intensity Modulated Radiation Therapy
  • +3 more
  • (no location specified)
Jul 11, 2023

Advanced Hepatocellular Carcinoma That Has Failed at Systemic Therapy Trial in Tianjin (Cadonilimab Injection, Ramucirumab

Recruiting
  • Advanced Hepatocellular Carcinoma That Has Failed at Systemic Therapy
  • Cadonilimab Injection
  • Ramucirumab Injection
  • Tianjin, Tianjin, China
    Tianjin Cancer Hospital Airport Hospital
May 14, 2023

Head and Neck Squamous Cell Carcinoma, Locally Advanced Operable Trial in Guangzhou (Cadonilimab, Docetaxel, Cisplatin)

Recruiting
  • Head and Neck Squamous Cell Carcinoma
  • Locally Advanced Operable
  • Guangzhou, Guangdong, China
  • +1 more
Sep 4, 2023

Locally Advanced Rectal Carcinoma Trial (Cadonilimab Injection, Short-course radiotherapy, Consolidation chemo)

Not yet recruiting
  • Locally Advanced Rectal Carcinoma
  • Cadonilimab Injection
  • +2 more
  • (no location specified)
Mar 19, 2023